title: Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
authors.forename: S
authors.initials: S
authors.lastname: Ménard
authors.forename: T
authors.initials: T
authors.lastname: Camerini
authors.forename: L
authors.initials: L
authors.lastname: Mariani
authors.forename: G
authors.initials: G
authors.lastname: Tomasic
authors.forename: S
authors.initials: S
authors.lastname: Pilotti
authors.forename: A
authors.initials: A
authors.lastname: Costa
authors.forename: G
authors.initials: G
authors.lastname: De Palo
authors.forename: U
authors.initials: U
authors.lastname: Veronesi
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D017313:Fenretinide / Q000627:therapeutic use*; D006801:Humans; D008593:Menopause; D016609:Neoplasms, Second Primary / Q000517:prevention & control*; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D017313:Fenretinide